Announcements Trials
Browse Landscape

Phase

Phase 1 3

Status

Terminated 1Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 3Dermatologic 2Thoracic 1Sarcoma 1Head & Neck 1Gastrointestinal 1

Conditions

Melanoma 8Carcinoma, Non-Small-Cell Lung 7Pancreatic Neoplasms 6Colorectal Neoplasms 6Stomach Neoplasms 5Carcinoma, Renal Cell 5Uterine Cervical Neoplasms 4Squamous Cell Carcinoma of Head and Neck 4Rectal Neoplasms 4Neoplasms 4Nasopharyngeal Carcinoma 4Triple Negative Breast Neoplasms 3Neoplasm Metastasis 3Esophageal Squamous Cell Carcinoma 3Endometrial Neoplasms 3Skin Neoplasms 2Prostatic Neoplasms 2Ovarian Neoplasms 2Lung Neoplasms 2Glioblastoma 2Advanced Solid Tumors 2von Hippel-Lindau Disease 1Thyroid cancer, follicular 1Thyroid cancer, Hurthle cell 1Thyroid Neoplasms 1Thyroid Cancer, Papillary 1Stomach Adenocarcinoma 1Solid Tumors 1Solid Tumor, Adult 1Solid Tumor 1

Interventions

pembrolizumab 96Carboplatin 67Paclitaxel 56Cyclophosphamide 40Capecitabine 30Specimen Handling 28sacituzumab govitecan 26130-nm albumin-bound paclitaxel 25Gemcitabine 22Magnetic Resonance Spectroscopy 21olaparib 20Doxorubicin 20Albumin-Bound Paclitaxel 20Taxes 19Biopsy 19Drug Therapy 16atezolizumab 14Nivolumab 14toripalimab 12Radiotherapy 12Epirubicin 12durvalumab 11Docetaxel 10Cisplatin 10Bevacizumab 10eribulin 9fludarabine 8Standard of Care 7Radiation 7Injections 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Triple Negative Breast Neoplasms × spartalizumab × 1 year × Clear all
NCT03891953 2026-01-21

Study of Safety and Efficacy of DKY709 Alone or in Combination With PDR001 in Patients With Advanced Solid Tumors.

Novartis

Phase 1 Active not recruiting
98 enrolled
BreastDermatologicHead & NeckThoracic

Nasopharyngeal Carcinoma, Carcinoma, Non-Small-Cell Lung, Melanoma, Triple Negative Breast Neoplasms

NCT02936102 2025-11-14

A Study of FAZ053 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.

Novartis

Phase 1 Terminated
154 enrolled
BreastSarcoma

Chordoma, Sarcoma, Alveolar Soft Part, Triple Negative Breast Neoplasms

NCT01351103 2025-06-13

A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands

Novartis

Phase 1 Completed
185 enrolled
BreastDermatologicGastrointestinal

Esophageal Squamous Cell Carcinoma, Melanoma, Pancreatic Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡